Rhea-AI Summary
MyoKardia, Inc. (MYOK) reported its financial results for Q1 2020, highlighting a net loss of $69.9 million, or $1.50 per share, up from a loss of $37.5 million in Q1 2019. Cash and investments decreased to $360.1 million from $430.3 million as of December 31, 2019, with guidance suggesting sufficient funds into H2 2021. While clinical trial advancements were noted, including results from the MAVERICK-HCM trial, new patient enrollment has been paused due to COVID-19. R&D expenses rose to $51.9 million, driven by increased personnel costs and clinical program advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags